Biohaven Ltd. (NYSE:BHVN) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG grew its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 25.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 169,773 shares of the company's stock after acquiring an additional 33,987 shares during the quarter. Deutsche Bank AG owned about 0.17% of Biohaven worth $6,341,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. DAFNA Capital Management LLC raised its stake in Biohaven by 17.7% in the 4th quarter. DAFNA Capital Management LLC now owns 220,235 shares of the company's stock valued at $8,226,000 after purchasing an additional 33,105 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Biohaven during the fourth quarter worth $884,000. Boone Capital Management LLC acquired a new stake in shares of Biohaven in the fourth quarter valued at about $13,499,000. Brown Advisory Inc. lifted its stake in shares of Biohaven by 0.7% in the fourth quarter. Brown Advisory Inc. now owns 975,585 shares of the company's stock worth $36,438,000 after buying an additional 7,226 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Biohaven by 40.5% in the fourth quarter. Bank of America Corp DE now owns 310,559 shares of the company's stock worth $11,599,000 after buying an additional 89,576 shares in the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BHVN. Robert W. Baird dropped their price objective on shares of Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a research note on Monday, April 28th. Cantor Fitzgerald upgraded Biohaven to a "strong-buy" rating in a report on Tuesday, May 13th. Royal Bank of Canada lowered Biohaven from an "outperform" rating to a "sector perform" rating and dropped their price target for the company from $54.00 to $21.00 in a research report on Monday. JPMorgan Chase & Co. reduced their price objective on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Finally, Morgan Stanley lowered their price objective on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $59.46.

Biohaven Price Performance

Shares of NYSE:BHVN traded down $0.52 during midday trading on Wednesday, reaching $15.74. 2,867,732 shares of the company's stock were exchanged, compared to its average volume of 1,229,211. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -1.68 and a beta of 1.18. Biohaven Ltd. has a fifty-two week low of $14.69 and a fifty-two week high of $55.70. The firm's 50 day simple moving average is $21.79 and its two-hundred day simple moving average is $33.72.

Biohaven (NYSE:BHVN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.50). Equities research analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Insider Transactions at Biohaven

In other news, Director John W. Childs acquired 32,700 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This represents a 1.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 16.00% of the company's stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.